Company Overview and News

 
117 Monthly Pay Canadian Dividend Stocks Cast 2% To 23% Yields To July 2019

2018-07-03 seekingalpha
Monthly Paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead once, twice, or four times.
CCAOF CJ FFN CBL NAF.UN CRLFF AD ALARF CRIUF MHIVF CHW.DB CJR.B CHW EFRTF AHOTF CNDCF GXOCF BK CHWWF CGIFF DVSPF CJREF GXO FNCSF

 
119 Monthly Pay Canadian Dividend Stocks Show 1% To 19% Yields To June 2019

2018-06-02 seekingalpha
Monthly Paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead once, twice, or four times.
CCAOF EBGUF FFN CBL NAF.UN AD ALARF CRIUF BNEFF CHW.DB SOT.UN CJR.B CHW MR.UN AHOTF OSP CNDCF BK CHWWF CGIFF BNE LCS CJREF FNCSF

 
BRIEF-Chesswood Qtrly Earnings Per Share $0.76

2018-03-12 reuters
* CHESSWOOD GROUP - 2017 NET INCOME INCLUDES TAX RECOVERY OF $9.4 MILLION AS A RESULT OF U.S. TAX REFORM Source text for Eikon: Further company coverage:
CHWWF CHW CHW.DB

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:CHW / Chesswood Group Limited on message board site Silicon Investor.

Charles Schwab (SCH) -- A tech-stock profile? Charles Schwab (SCH) -- A tech-stock profile? Charles Schwab (SCH) -- A tech-stock profile? E.Schwab problems E.Schwab problems E.Schwab problems
SCHWAB IPO ALERT THREAD SCHWAB IPO ALERT THREAD SCHWAB IPO ALERT THREAD eSchwab eSchwab eSchwab
SCH: Charles Schwab Corp. SCH: Charles Schwab Corp. SCH: Charles Schwab Corp. Arnold Schwarzenegger Pre-Pre Election Advisory Panel Arnold Schwarzenegger Pre-Pre Election Advisory Panel Arnold Schwarzenegger Pre-Pre Election Advisory Panel
SCHWAB is the one of the worst SCHWAB is the one of the worst SCHWAB is the one of the worst CSG: Cadbury Schweppes plc CSG: Cadbury Schweppes plc CSG: Cadbury Schweppes plc
Speechworks(SPWX) Speechworks(SPWX) Speechworks(SPWX) Complaints About Schwab Complaints About Schwab Complaints About Schwab